Mariana-Emilia Caragea
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mariana-Emilia Caragea has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Lidia Boldeanu
Department of Microbiology, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania
8 shared publications - Mihail Virgil Boldeanu
Department of Immunology, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania
7 shared publications - Mohamed-Zakaria Assani
Doctoral School, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania
7 shared publications - Cristin Constantin Vere
Research Center of Gastroenterology and Hepatology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania
5 shared publications - Daniel Cosmin Caragea
Department of Nephrology, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania
5 shared publications - Isabela Siloși
Department of Immunology, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania
4 shared publications
Latest Publications
- Open Access
- 5 July 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (13) , 6038
Cutaneous Staphylococcus aureus Infections in Renal Edema Across Kidney Disease and the Intensive Care Unit: Pathophysiological Mechanisms, Clinical Implications, and Therapeutic Challenges
Staphylococcus aureus, particularly methicillin-resistant S. aureus (MRSA), remains a leading cause of skin and soft tissue infections (SSTIs) worldwide. Patients with renal edema, including those with nephrotic syndrome and chronic kidney disease (CKD), and critical illness, are particularly susceptible because of barrier dysfunction, immune impairment, and altered antimicrobial pharmacokinetics. This narrative review examines the mechanisms linking renal edema to increased susceptibility to cutaneous S. aureus infection and discusses their diagnostic and therapeutic implications. Three interconnected pathophysiological pathways appear central to this susceptibility: disruption of the cutaneous barrier, nephrotic and uremic immune dysfunction, and impaired lymphatic immune surveillance. These abnormalities facilitate bacterial colonization, and invasion, while S. aureus further exploits the renal host through adhesins, toxins, biofilm formation, and immune-evasion mechanisms. The review also highlights the challenges of managing severe staphylococcal infections in patients with kidney disease and critical illness, where augmented renal clearance, expanded volume of distribution, extracorporeal renal support, and fluctuating renal function may substantially influence antimicrobial exposure. Current management requires early recognition, source control, individualized antimicrobial selection, renal-adapted dosing, therapeutic drug monitoring, and antimicrobial stewardship. Although emerging anti-virulence and immunomodulatory strategies show promise, most remain at the preclinical or early translational stage. Overall, renal edema should be regarded as a biologically active modifier of host–pathogen interactions that contributes to increased susceptibility to cutaneous S. aureus infection across the spectrum of kidney disease.
- 5 July 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (13) , 6038
Open AccessCutaneous Staphylococcus aureus Infections in Renal Edema Across Kidney Disease and the Intensive Care Unit: Pathophysiological Mechanisms, Clinical Implications, and Therapeutic Challenges
Staphylococcus aureus, particularly methicillin-resistant S. aureus (MRSA), remains a leading cause of skin and soft tissue infections (SSTIs) worldwide. Patients with renal edema, including those with nephrotic syndrome and chronic kidney disease (CKD), and critical illness, are particularly susceptible because of barrier dysfunction, immune impairment, and altered antimicrobial pharmacokinetics. This narrative review examines the mechanisms linking renal edema to increased susceptibility to cutaneous S. aureus infection and discusses their diagnostic and therapeutic implications. Three interconnected pathophysiological pathways appear central to this susceptibility: disruption of the cutaneous barrier, nephrotic and uremic immune dysfunction, and impaired lymphatic immune surveillance. These abnormalities facilitate bacterial colonization, and invasion, while S. aureus further exploits the renal host through adhesins, toxins, biofilm formation, and immune-evasion mechanisms. The review also highlights the challenges of managing severe staphylococcal infections in patients with kidney disease and critical illness, where augmented renal clearance, expanded volume of distribution, extracorporeal renal support, and fluctuating renal function may substantially influence antimicrobial exposure. Current management requires early recognition, source control, individualized antimicrobial selection, renal-adapted dosing, therapeutic drug monitoring, and antimicrobial stewardship. Although emerging anti-virulence and immunomodulatory strategies show promise, most remain at the preclinical or early translational stage. Overall, renal edema should be regarded as a biologically active modifier of host–pathogen interactions that contributes to increased susceptibility to cutaneous S. aureus infection across the spectrum of kidney disease.
- Open Access
- 31 May 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (11) , 4999
Mechanisms Linking Recurrent Bacterial Urinary Tract Infections to Chronic Kidney Disease Progression
Urinary tract infections (UTIs) are among the most common bacterial infections worldwide and are traditionally considered acute and self-limited conditions. However, growing evidence suggests that recurrent or persistent UTIs may contribute to chronic kidney disease (CKD) progression through complex interactions between uropathogens and host responses. This review examines the pathophysiological links of UTIs caused by uropathogenic Escherichia coli, Klebsiella spp., and Enterococcus spp. and the development of chronic renal injury. Pathogen-specific persistence mechanisms, including intracellular survival, biofilm formation, and chronic colonization, may promote sustained inflammation, oxidative stress, and maladaptive repair responses. These processes are associated with tubular injury and progressive fibrotic remodeling. In addition, host-related factors such as diabetes, immune dysfunction, and antimicrobial resistance may further influence disease progression. Emerging biomarkers of inflammation, tubular injury, and fibrosis may improve early detection and risk stratification in patients with recurrent or complicated UTIs. Collectively, these findings support the concept that recurrent UTIs may represent potential contributors to CKD progression in susceptible individuals and highlight the importance of early recognition, pathogen-oriented management, and improved diagnostic strategies.
- 31 May 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (11) , 4999
Open AccessMechanisms Linking Recurrent Bacterial Urinary Tract Infections to Chronic Kidney Disease Progression
Urinary tract infections (UTIs) are among the most common bacterial infections worldwide and are traditionally considered acute and self-limited conditions. However, growing evidence suggests that recurrent or persistent UTIs may contribute to chronic kidney disease (CKD) progression through complex interactions between uropathogens and host responses. This review examines the pathophysiological links of UTIs caused by uropathogenic Escherichia coli, Klebsiella spp., and Enterococcus spp. and the development of chronic renal injury. Pathogen-specific persistence mechanisms, including intracellular survival, biofilm formation, and chronic colonization, may promote sustained inflammation, oxidative stress, and maladaptive repair responses. These processes are associated with tubular injury and progressive fibrotic remodeling. In addition, host-related factors such as diabetes, immune dysfunction, and antimicrobial resistance may further influence disease progression. Emerging biomarkers of inflammation, tubular injury, and fibrosis may improve early detection and risk stratification in patients with recurrent or complicated UTIs. Collectively, these findings support the concept that recurrent UTIs may represent potential contributors to CKD progression in susceptible individuals and highlight the importance of early recognition, pathogen-oriented management, and improved diagnostic strategies.
- Open Access
- 28 May 2026
- Published by MDPI AG in Preprints.org
Cutaneous Staphylococcus aureus Infections in Patients with Renal Edema: Pathophysiological Links, Clinical Implications, Therapeutic Perspectives, and Management in the Intensive Care Unit
Background: Staphylococcus aureus — particularly methicillin-resistant S. aureus (MRSA) — remains one of the leading causes of skin and soft tissue infections (SSTIs) worldwide. Patients with renal edema, including those with nephrotic syndrome and chronic kidney disease (CKD), represent a population of increased susceptibility due to combined barrier dysfunction, immune impairment, and altered pharmacokinetics. Despite its substantial clinical relevance, the mechanistic relationship between renal edema and cutaneous staphylococcal infection has received limited integrative attention. Objectives: This narrative review aims to: (1) examine the pathophysiological mechanisms through which renal edema predisposes to cutaneous S. aureus infection; (2) characterize the virulence mechanisms that facilitate bacterial persistence and invasion in the renal host; (3) describe the clinical spectrum of SSTIs in this population; (4) evaluate current and emerging therapeutic strategies adapted to renal dysfunction; and (5) discuss the management challenges of severe S. aureus infection in critically ill renal patients. Methods: Search terms included combinations of Staphylococcus aureus, MRSA, skin and soft tissue infections, renal edema, nephrotic syndrome, chronic kidney disease, ICU, vancomycin pharmacokinetics, augmented renal clearance, and anti-virulence therapy. Priority was given to clinical guidelines, systematic reviews, translational studies, and landmark investigations relevant to the pathophysiology and management of cutaneous staphylococcal infection in renal disease. Results: Three converging pathophysiological axes appear to underlie the increased susceptibility of patients with renal edema to cutaneous S. aureus infection: (1) mechanical barrier disruption caused by edema-associated skin tension, blistering, fissuring, and proteinaceous exudate; (2) nephrotic and uremic immunodeficiency, including urinary immunoglobulin loss, neutrophil dysfunction mediated by protein-bound uremic retention solutes (PBURS), complement depletion, and T-cell dysregulation; and (3) lymphatic dysfunction impairing regional immune surveillance and antigen clearance. S. aureus exploits these abnormalities through adhesins, toxin-mediated tissue injury, biofilm formation, and coordinated immune evasion pathways regulated in part by the ArlRS/MgrA cascade. In critically ill patients, management is further complicated by major pharmacokinetic variability, including augmented renal clearance, expanded volume of distribution, and extracorporeal renal support, necessitating individualized dosing strategies and AUC/MIC-guided vancomycin monitoring. Emerging anti-virulence approaches targeting alpha-toxin, quorum-sensing systems, and immune evasion pathways represent promising adjunctive therapeutic strategies. Conclusions: Renal edema creates a biologically permissive environment for cutaneous S. aureus infection through the interaction of barrier dysfunction, immune impairment, and altered antimicrobial pharmacokinetics. Optimal management requires early recognition, renal-adapted antimicrobial therapy, therapeutic drug monitoring, source control, and multidisciplinary care. Continued development of anti-virulence and immunomodulatory therapies may further improve outcomes in this vulnerable patient population.
- 28 May 2026
- Published by MDPI AG in Preprints.org
Open AccessCutaneous Staphylococcus aureus Infections in Patients with Renal Edema: Pathophysiological Links, Clinical Implications, Therapeutic Perspectives, and Management in the Intensive Care Unit
Background: Staphylococcus aureus — particularly methicillin-resistant S. aureus (MRSA) — remains one of the leading causes of skin and soft tissue infections (SSTIs) worldwide. Patients with renal edema, including those with nephrotic syndrome and chronic kidney disease (CKD), represent a population of increased susceptibility due to combined barrier dysfunction, immune impairment, and altered pharmacokinetics. Despite its substantial clinical relevance, the mechanistic relationship between renal edema and cutaneous staphylococcal infection has received limited integrative attention. Objectives: This narrative review aims to: (1) examine the pathophysiological mechanisms through which renal edema predisposes to cutaneous S. aureus infection; (2) characterize the virulence mechanisms that facilitate bacterial persistence and invasion in the renal host; (3) describe the clinical spectrum of SSTIs in this population; (4) evaluate current and emerging therapeutic strategies adapted to renal dysfunction; and (5) discuss the management challenges of severe S. aureus infection in critically ill renal patients. Methods: Search terms included combinations of Staphylococcus aureus, MRSA, skin and soft tissue infections, renal edema, nephrotic syndrome, chronic kidney disease, ICU, vancomycin pharmacokinetics, augmented renal clearance, and anti-virulence therapy. Priority was given to clinical guidelines, systematic reviews, translational studies, and landmark investigations relevant to the pathophysiology and management of cutaneous staphylococcal infection in renal disease. Results: Three converging pathophysiological axes appear to underlie the increased susceptibility of patients with renal edema to cutaneous S. aureus infection: (1) mechanical barrier disruption caused by edema-associated skin tension, blistering, fissuring, and proteinaceous exudate; (2) nephrotic and uremic immunodeficiency, including urinary immunoglobulin loss, neutrophil dysfunction mediated by protein-bound uremic retention solutes (PBURS), complement depletion, and T-cell dysregulation; and (3) lymphatic dysfunction impairing regional immune surveillance and antigen clearance. S. aureus exploits these abnormalities through adhesins, toxin-mediated tissue injury, biofilm formation, and coordinated immune evasion pathways regulated in part by the ArlRS/MgrA cascade. In critically ill patients, management is further complicated by major pharmacokinetic variability, including augmented renal clearance, expanded volume of distribution, and extracorporeal renal support, necessitating individualized dosing strategies and AUC/MIC-guided vancomycin monitoring. Emerging anti-virulence approaches targeting alpha-toxin, quorum-sensing systems, and immune evasion pathways represent promising adjunctive therapeutic strategies. Conclusions: Renal edema creates a biologically permissive environment for cutaneous S. aureus infection through the interaction of barrier dysfunction, immune impairment, and altered antimicrobial pharmacokinetics. Optimal management requires early recognition, renal-adapted antimicrobial therapy, therapeutic drug monitoring, source control, and multidisciplinary care. Continued development of anti-virulence and immunomodulatory therapies may further improve outcomes in this vulnerable patient population.
- Open Access
- 6 April 2026
- Published by MDPI AG in Preprints.org
From Infection to Fibrosis: The Role of Uropathogens in Chronic Kidney Disease Progression
Urinary tract infections (UTIs) are among the most common bacterial infections worldwide and are traditionally considered acute and self-limited conditions. However, emerging evidence suggests that recurrent and persistent UTIs may contribute to chronic kidney disease (CKD) progression through complex interactions between uropathogens and host responses. This review examines the pathophysiological mechanisms linking UTIs caused by uropathogenic Escherichia coli, Klebsiella spp., and Enterococcus spp. to CKD development. Distinct pathogen-specific strategies, including intracellular persistence, biofilm formation, and chronic colonization, enable sustained infection and recurrent inflammatory insults. These processes activate key molecular pathways, including innate immune signalling, inflammasome activation, oxidative stress, and fibrotic remodelling. The convergence of these mechanisms leads to tubular injury, nephron loss, and a progressive decline in renal function. A comprehensive mechanistic model integrating pathogen-specific persistence strategies and host-mediated responses, including inflammation, inflammasome activation, oxidative stress, and fibrosis, is illustrated in Figure X, highlighting how recurrent and persistent UTIs may drive CKD progression. In addition, biomarkers reflecting inflammation (IL-6, CRP), tubular injury (NGAL, KIM-1), and fibrosis (TGF-β, fibronectin) provide a translational bridge between molecular mechanisms and clinical practice. Host factors such as diabetes, immune dysfunction, and microbiome alterations further modulate disease trajectory, while antibiotic resistance contributes to persistent infection and increased renal risk. These findings underscore the importance of early detection, pathogen-specific management, and biomarker-guided monitoring. Collectively, this review supports a paradigm shift recognizing UTIs not merely as acute infections but also as potential contributors to CKD progression, with important implications for prevention and therapeutic strategies.
- 6 April 2026
- Published by MDPI AG in Preprints.org
Open AccessFrom Infection to Fibrosis: The Role of Uropathogens in Chronic Kidney Disease Progression
Urinary tract infections (UTIs) are among the most common bacterial infections worldwide and are traditionally considered acute and self-limited conditions. However, emerging evidence suggests that recurrent and persistent UTIs may contribute to chronic kidney disease (CKD) progression through complex interactions between uropathogens and host responses. This review examines the pathophysiological mechanisms linking UTIs caused by uropathogenic Escherichia coli, Klebsiella spp., and Enterococcus spp. to CKD development. Distinct pathogen-specific strategies, including intracellular persistence, biofilm formation, and chronic colonization, enable sustained infection and recurrent inflammatory insults. These processes activate key molecular pathways, including innate immune signalling, inflammasome activation, oxidative stress, and fibrotic remodelling. The convergence of these mechanisms leads to tubular injury, nephron loss, and a progressive decline in renal function. A comprehensive mechanistic model integrating pathogen-specific persistence strategies and host-mediated responses, including inflammation, inflammasome activation, oxidative stress, and fibrosis, is illustrated in Figure X, highlighting how recurrent and persistent UTIs may drive CKD progression. In addition, biomarkers reflecting inflammation (IL-6, CRP), tubular injury (NGAL, KIM-1), and fibrosis (TGF-β, fibronectin) provide a translational bridge between molecular mechanisms and clinical practice. Host factors such as diabetes, immune dysfunction, and microbiome alterations further modulate disease trajectory, while antibiotic resistance contributes to persistent infection and increased renal risk. These findings underscore the importance of early detection, pathogen-specific management, and biomarker-guided monitoring. Collectively, this review supports a paradigm shift recognizing UTIs not merely as acute infections but also as potential contributors to CKD progression, with important implications for prevention and therapeutic strategies.
- Open Access
Beyond HOMA-IR: Comparative Evaluation of Insulin Resistance and Anthropometric Indices Across Prediabetes and Type 2 Diabetes Mellitus in Metabolic Syndrome Patients
Insulin resistance is central in metabolic syndrome, but indices such as Homeostasis Model Assessment-estimated Insulin Resistance (HOMA-IR) require insulin assays that are costly and not always available. Non-insulin-based indices and refined anthropometric markers may offer simpler risk stratification in prediabetes and diabetes. Our objective was to compare insulin and non-insulin-based indices of insulin resistance, together with advanced anthropometric and lipid markers, between prediabetes (PreDM) and type 2 diabetes (T2DM) and across hypertension grades in metabolic syndrome. We conducted a cross-sectional study in 200 adults with metabolic syndrome, 80 with PreDM and 120 with T2DM. Clinical, anthropometric and biochemical parameters were recorded, and HOMA-IR, Homeostasis Model Assessment of Beta-cell function (HOMA%B), Metabolic Score for Insulin Resistance (METS-IR), triglyceride to glucose index (TyG), triglyceride-to-glucose index to high-density lipoprotein cholesterol ratio (TyG/HDL-c) and other derived indices were calculated. Group comparisons, correlations and multiple linear regression were performed. Compared with PreDM, T2DM showed higher glycemic indices and inflammation, but similar body mass index (BMI) and triglycerides. Across glycemic categories and hypertension grades, METS-IR, TyG and TyG/HDL-c increased and correlated strongly with body roundness index (BRI), abdominal volume index (AVI) and weight-adjusted waist index (WWI), while HOMA-IR contributed little independent information. In regression models, lipid adipose product (LAP) and WWI best explained METS-IR in prediabetes, whereas TyG and BRI were the main determinants of METS-IR in diabetes. In metabolic syndrome with PreDM or T2DM, METS-IR and TyG, particularly combined with BRI, AVI and WWI, outperformed traditional lipid ratios and added value beyond HOMA-IR. These composite indices appear useful for insulin resistance assessment when insulin measurement is unavailable or unreliable.
Open AccessBeyond HOMA-IR: Comparative Evaluation of Insulin Resistance and Anthropometric Indices Across Prediabetes and Type 2 Diabetes Mellitus in Metabolic Syndrome Patients
Insulin resistance is central in metabolic syndrome, but indices such as Homeostasis Model Assessment-estimated Insulin Resistance (HOMA-IR) require insulin assays that are costly and not always available. Non-insulin-based indices and refined anthropometric markers may offer simpler risk stratification in prediabetes and diabetes. Our objective was to compare insulin and non-insulin-based indices of insulin resistance, together with advanced anthropometric and lipid markers, between prediabetes (PreDM) and type 2 diabetes (T2DM) and across hypertension grades in metabolic syndrome. We conducted a cross-sectional study in 200 adults with metabolic syndrome, 80 with PreDM and 120 with T2DM. Clinical, anthropometric and biochemical parameters were recorded, and HOMA-IR, Homeostasis Model Assessment of Beta-cell function (HOMA%B), Metabolic Score for Insulin Resistance (METS-IR), triglyceride to glucose index (TyG), triglyceride-to-glucose index to high-density lipoprotein cholesterol ratio (TyG/HDL-c) and other derived indices were calculated. Group comparisons, correlations and multiple linear regression were performed. Compared with PreDM, T2DM showed higher glycemic indices and inflammation, but similar body mass index (BMI) and triglycerides. Across glycemic categories and hypertension grades, METS-IR, TyG and TyG/HDL-c increased and correlated strongly with body roundness index (BRI), abdominal volume index (AVI) and weight-adjusted waist index (WWI), while HOMA-IR contributed little independent information. In regression models, lipid adipose product (LAP) and WWI best explained METS-IR in prediabetes, whereas TyG and BRI were the main determinants of METS-IR in diabetes. In metabolic syndrome with PreDM or T2DM, METS-IR and TyG, particularly combined with BRI, AVI and WWI, outperformed traditional lipid ratios and added value beyond HOMA-IR. These composite indices appear useful for insulin resistance assessment when insulin measurement is unavailable or unreliable.
- Open Access
- 1 November 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (21) , 10670
Assessment of AOPP, TBARS, and Inflammatory Status in Diabetic Nephropathy and Hemodialyzed Patients
We compared oxidative markers and their links to inflammation in diabetic nephropathy and hemodialysis to identify independent determinants. We studied 180 adults, 90 patients with type 2 diabetes and diabetic nephropathy and 90 patients on hemodialysis. We measured serum advanced oxidation protein products (AOPP) and thiobarbituric acid reactive substances (TBARS) by enzyme-linked immunosorbent assay (ELISA). Partial correlations were adjusted for age, sex, and albumin with false discovery rate (FDR) control. Principal component analysis (PCA) summarized inflammatory indices and linear models tested predictors of AOPP and TBARS. Oxidative damage was higher in hemodialysis, with AOPP median 25.80 versus 5.06 and TBARS 8.49 versus 1.89, p less than 0.0001. C reactive protein (CRP) and mean corpuscular volume-to-lymphocyte ratio (MCVL) were higher in patients ongoing hemodialysis; systemic immune-inflammation index (SII) was higher in diabetic nephropathy. PCA yielded a dominant inflammation axis in both cohorts, 74.73 percent in hemodialysis and 85.20 percent in diabetic nephropathy. In regression, creatinine (β = 2.47, p = 0.026) predicted AOPP in hemodialysis. Dialysis vintage inversely predicted TBARS, β = −0.2305, p = 0.0209. In diabetic nephropathy, the PCA inflammation score predicted AOPP, β = 1.134, p = 0.0003. Protein oxidation tracked systemic inflammation in diabetic nephropathy, but not in hemodialysis. AOPP outperformed TBARS as an inflammatory partner and a practical monitoring candidate in diabetic kidney disease. Prospective studies should test for prognostic value and therapy sensitivity.
- 1 November 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (21) , 10670
Open AccessAssessment of AOPP, TBARS, and Inflammatory Status in Diabetic Nephropathy and Hemodialyzed Patients
We compared oxidative markers and their links to inflammation in diabetic nephropathy and hemodialysis to identify independent determinants. We studied 180 adults, 90 patients with type 2 diabetes and diabetic nephropathy and 90 patients on hemodialysis. We measured serum advanced oxidation protein products (AOPP) and thiobarbituric acid reactive substances (TBARS) by enzyme-linked immunosorbent assay (ELISA). Partial correlations were adjusted for age, sex, and albumin with false discovery rate (FDR) control. Principal component analysis (PCA) summarized inflammatory indices and linear models tested predictors of AOPP and TBARS. Oxidative damage was higher in hemodialysis, with AOPP median 25.80 versus 5.06 and TBARS 8.49 versus 1.89, p less than 0.0001. C reactive protein (CRP) and mean corpuscular volume-to-lymphocyte ratio (MCVL) were higher in patients ongoing hemodialysis; systemic immune-inflammation index (SII) was higher in diabetic nephropathy. PCA yielded a dominant inflammation axis in both cohorts, 74.73 percent in hemodialysis and 85.20 percent in diabetic nephropathy. In regression, creatinine (β = 2.47, p = 0.026) predicted AOPP in hemodialysis. Dialysis vintage inversely predicted TBARS, β = −0.2305, p = 0.0209. In diabetic nephropathy, the PCA inflammation score predicted AOPP, β = 1.134, p = 0.0003. Protein oxidation tracked systemic inflammation in diabetic nephropathy, but not in hemodialysis. AOPP outperformed TBARS as an inflammatory partner and a practical monitoring candidate in diabetic kidney disease. Prospective studies should test for prognostic value and therapy sensitivity.
- Open Access
- 27 March 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (7) , 3081
The Involvement of Serotonin in the Obesity Pathway—A Last Decade Systematic Review of the Literature
Obesity represents a complex, multifactorial syndrome that represents a high burden for public health systems worldwide. Serotonin is an important factor in feeding behavior and weight regulation and their interplay implies multiple mechanisms that could explain the correlation with obesity, so understanding these interconnections is essential for developing targeted therapeutic strategies. A systematic review of the literature was conducted using PubMed and Scopus databases, using articles published between 1 January 2015 and 1 December 2024, based on predefined inclusion and exclusion criteria. After the selection process, 22 studies were selected for detailed analysis, focusing on the role of serotonin in obesity. Serotonin significantly influences appetite control and energy homeostasis through multiples pathways, including insulin resistance, high-fat diets, gut microbiota, low-grade inflammation, interferences with tryptophan metabolism, psychiatric modifications, genetic alterations of serotonin receptors, serotonin implications in eating behavior, and neurohormonal regulation of appetite. This review highlights the multidimensional characteristics of the serotonin–obesity association, along with its significance in metabolic and psychiatric pathologies. In order to develop more efficient methods for managing obesity, future studies should concentrate on serotonergic regulation and complex management strategies involving the neurohormonal axis.
- 27 March 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (7) , 3081
Open AccessThe Involvement of Serotonin in the Obesity Pathway—A Last Decade Systematic Review of the Literature
Obesity represents a complex, multifactorial syndrome that represents a high burden for public health systems worldwide. Serotonin is an important factor in feeding behavior and weight regulation and their interplay implies multiple mechanisms that could explain the correlation with obesity, so understanding these interconnections is essential for developing targeted therapeutic strategies. A systematic review of the literature was conducted using PubMed and Scopus databases, using articles published between 1 January 2015 and 1 December 2024, based on predefined inclusion and exclusion criteria. After the selection process, 22 studies were selected for detailed analysis, focusing on the role of serotonin in obesity. Serotonin significantly influences appetite control and energy homeostasis through multiples pathways, including insulin resistance, high-fat diets, gut microbiota, low-grade inflammation, interferences with tryptophan metabolism, psychiatric modifications, genetic alterations of serotonin receptors, serotonin implications in eating behavior, and neurohormonal regulation of appetite. This review highlights the multidimensional characteristics of the serotonin–obesity association, along with its significance in metabolic and psychiatric pathologies. In order to develop more efficient methods for managing obesity, future studies should concentrate on serotonergic regulation and complex management strategies involving the neurohormonal axis.
- Open Access
- 7 December 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (12) , 2786
The Role of Dopamine in Gastric Cancer—A Systematic Review of the Pathogenesis Phenomena Developments
Background: In the last few decades, it has been emphasized that dopamine, a well-known neurotransmitter with multiple roles in central nervous system, is also implicated in the activity of peripheral tissues and organs, more specifically influencing the gastrointestinal system (GI). Methods: We registered a protocol under the CRD42024547935 identifier in the Prospero register of systematic reviews. Furthermore, using the Population, Intervention, Comparison, Outcome, and Study Design strategy to guide our study rationale, and under the Preferred Reporting Items for Systematic reviews and Meta-Analyses recommendations, we conducted a qualitative systematic literature search based on the PubMed, Scopus, and Web of Science databases using the “gastric cancers AND dopamine” search criteria. We obtained 68 articles from PubMed, 142 articles from Scopus, and 99 articles from the Web of Science database. Results: Within gastric cancer biology, dopamine has notable effects on STAT-3 and DARPP-32. STAT-3, a transcription factor involved in cellular proliferation and invasion, plays a significant role in cancer progression. Conclusions: Understanding the roles of dopamine in cancer, beyond aspects such as cancer cell invasion, immune response modulation, or tumor growth, could guide the development of new cancer therapies by modulating its pathways, especially the DARPP-32/CXCR4/CXCL-12 complex axis, in order to improve the morbidity and mortality caused by this type of cancer.
- 7 December 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (12) , 2786
Open AccessThe Role of Dopamine in Gastric Cancer—A Systematic Review of the Pathogenesis Phenomena Developments
Background: In the last few decades, it has been emphasized that dopamine, a well-known neurotransmitter with multiple roles in central nervous system, is also implicated in the activity of peripheral tissues and organs, more specifically influencing the gastrointestinal system (GI). Methods: We registered a protocol under the CRD42024547935 identifier in the Prospero register of systematic reviews. Furthermore, using the Population, Intervention, Comparison, Outcome, and Study Design strategy to guide our study rationale, and under the Preferred Reporting Items for Systematic reviews and Meta-Analyses recommendations, we conducted a qualitative systematic literature search based on the PubMed, Scopus, and Web of Science databases using the “gastric cancers AND dopamine” search criteria. We obtained 68 articles from PubMed, 142 articles from Scopus, and 99 articles from the Web of Science database. Results: Within gastric cancer biology, dopamine has notable effects on STAT-3 and DARPP-32. STAT-3, a transcription factor involved in cellular proliferation and invasion, plays a significant role in cancer progression. Conclusions: Understanding the roles of dopamine in cancer, beyond aspects such as cancer cell invasion, immune response modulation, or tumor growth, could guide the development of new cancer therapies by modulating its pathways, especially the DARPP-32/CXCR4/CXCL-12 complex axis, in order to improve the morbidity and mortality caused by this type of cancer.